Delgado-Diaz, David Jose
Jesaveluk, Brianna
Hayward, Joshua A.
Tyssen, David
Alisoltani, Arghavan
Potgieter, Matthys
Bell, Liam
Ross, Elizabeth
Iranzadeh, Arash
Allali, Imane
Dabee, Smritee
Barnabas, Shaun
Gamieldien, Hoyam
Blackburn, Jonathan M.
Mulder, Nicola
Smith, Steven B.
Edwards, Vonetta L.
Burgener, Adam D.
Bekker, Linda-Gail
Ravel, Jacques
Passmore, Jo-Ann S.
Masson, Lindi
Hearps, Anna C.
Tachedjian, Gilda
Funding for this research was provided by:
Monash Biomedicine Discovery Institute, Monash University
Australian Government Research Training Program
National Health and Medical Research Council (GNT1164982, GNT1164982, GNT1164982, GNT1164982, GNT1164982, GNT1164982)
European and Developing Countries Clinical Trials Partnership (SP.2011.41304.038)
South African Department of Science and Technology (DST/CON 0260/2012)
Carnegie Corporation of New York
South African National Research Foundation
Poliomyelitis Research Foundation
South African Medical Research Council
Article History
Received: 12 February 2022
Accepted: 30 July 2022
First Online: 31 August 2022
Declarations
:
: The Universities of Witwatersrand and Cape Town Research Ethics Committees approved the recruitment of women into the WISH study. Consent for participation was obtained as previously described [CitationRef removed].
: Not applicable.
: GT and ACH are coinventors on a patent application examining the immunomodulatory effects of L-lactic acid on cervicovaginal epithelial cells. The other authors declare that they have no competing interests.